Don�� read too much into the congressional compromise on the budget. Though the deal was accompanied by a rare outbreak of bipartisanship, that cooperation won�� last.
SEE ALSO: Kiplinger's Economic Outlook
Liberals and conservatives in Congress, including tea party and mainstream Republicans, will disagree more than they concur in coming months. Fundamental philosophical differences will remain and familiar disputes will reemerge, particularly as November�� midterm elections get closer.
The ideological gulf will be on full display soon after the start of the new year, when lawmakers return to Washington to debate extending unemployment benefits for 1.3 million out-of-work Americans.
Some economists contend that the 7% jobless rate is argument enough to keep checks flowing to the long-term unemployed. Yet the extension wasn�� a big part of the negotiations between House Budget Committee Chairman Paul Ryan (R-WI) and Senate Budget Committee Chairman Patty Murray (D-WA).
NewLink Genetics Corporation (NewLink), incorporated on June 4, 1999, is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes biologic and small-molecule immunotherapy product candidates focused to treat a range of oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy (HyperAcute Pancreas), is being studied in a Phase-III clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA), with the United States Food and Drug Administration (FDA). It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy (HyperAcute Lung), which is being studied in a Phase-I/II clinical trial conducted at the National Cancer Institute (NCI), and its HyperAcute Melanoma cancer immunotherapy (HyperAcute Melanoma), which is being studied in an investigator-initiated Phase-II clinical trial.
The Company�� HyperAcute product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. It is also conducting small-molecule based research and development to produce new drugs capable of breaking the immune system's tolerance to cancer through inhibition of the indoleamine-(2,3)-dioxygenase (IDO), pathway. It is engaged in the study of IDO pathway inhibitor product candidate, d-1-methyltryptophan (D-1MT), in collaboration with the NCI, in two Phase 1B/II clinical trials.
HyperAcute Cancer Immunotherapy Product Candidates
In May 2010, the Company initiated Phase-III clinical trial for HyperAcute Pancreas. Its second product candidate, HyperAcute Lung, is in a Phase I/II clinical trial that is enrolled with 54 patients for the treatment of refractory, recurrent or metastatic nonresectable non-small cell lung cancer (NSCLC). Its Hyper! Acute Melanoma product candidate is being studied in an investigator-initiated, fully enrolled 25 patient Phase-II clinical trial for the treatment of advanced melanoma.
HyperAcute Cancer Immunotherapy Technology
The Company�� HyperAcute immunotherapies operate by exploiting a natural barrier present in humans that protects against infection being transmitted from other mammals. This barrier is related to the enzyme, alpha (1,3) galactosyl transferase, which is expressed in the cells of lower mammals. The presence of this enzyme results in the expression of a non-human form of carbohydrate called alpha (1,3) galactosyl carbohydrates (a-Gal), on the surface of affected cells. Its HyperAcute immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes a-Gal epitopes. This exposure to a-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on, which a-Gal is present by activating complement.
IDO Pathway Inhibitor Product Candidate
The Company is developing D-1MT, a small-molecule, orally bioavailable product candidate designed to inhibit the IDO pathway. In preclinical models, IDO pathway inhibitors have shown anti-tumor effects in combination with radiotherapy, chemotherapy, targeted therapy or immunotherapy. Through its collaboration with the NCI, it is studying D-1MT in two Phase 1B/II safety and efficacy clinical trials in various chemotherapy and immunotherapy combinations. One clinical trial combines D-1MT with an Ad-p53 autologous dendritic cell vaccine for solid malignancies with p53 mutations, such as lung, breast and colon cancers. The other clinical trial involves the combined use of D-1MT and Taxotere for patients with advanced stage solid tumors, for which Taxotere is the standard-of-care treatment, such as metastatic breast, prostate, ovarian and lung cancers.
Advisors' Opinion: - [By Jayson Derrick]
NewLink Genetics (NASDAQ: NLNK) announced that it will discontinue the phase 3 IMPRESS clinical trial of algenpantucel-L for patients with pancreatic cancer. The company intends to regroup and ��athering additional, more mature data in support of our mission to provide improved treatment options for patients with pancreatic cancer.��Shares fell 16.20 percent, closing at $31.60.
- [By Matt Egan]
Another big winner on Wednesday is NewLink Genetics (NLNK), which has the exclusive license to an experimental Ebola vaccine developed by the Public Health Agency of Canada. The FDA recently gave approval for Phase 1 clinical trials on the drug. Shares of NewLink are up 8%.
- [By Jake L'Ecuyer]
In trading on Thursday, healthcare shares were relative laggards, down on the day by about 0.64 percent. Top decliners in the sector included Sunesis Pharmaceuticals (NASDAQ: SNSS), off 5.6 percent, and NewLink Genetics (NASDAQ: NLNK), down 6.3 percent.
Top 10 Forestry Stocks To Buy For 2014: Crumbs Bake Shop Inc (CRMB)
Crumbs Bake Shop, Inc., formerly 57th Street General Acquisition Corp., incorporated on October 29, 2009, is owner of Crumbs Holdings LLC (Crumbs), a neighborhood bakery and a retailer of cupcakes. As of November 1, 2011, Crumbs had 43 locations, including 29 locations in the New York Metro area, nine locations on the West Coast, three locations in Washington, D.C., one location in Virginia and one location in Chicago. The specialty of the house is cupcakes; however, the menu also includes a blend of baked goods. On May 5, 2011, the Company merged with Crumbs.
The Company offers a range of Signature and Taste size cupcakes. Signature cupcakes are ordered in increments of six. One can create its own individual six packs or choose a pre-selected assortment. Its Taste size cupcakes are offered by the dozen in pre-selected favorites assortments. There are more than 60 varieties of cupcakes baked fresh daily with a new cupcake of the week debuting each Monday.
Advisors' Opinion: - [By Jack Kramer and Nick Martell]
2. Crumbs Cupcake stock continues to drop
Pour some sugar on me, baby, because the recent performance of cupcake-makin' chain Crumbs Bake Shop (NASDAQ: CRMB ) hasn't tasted good for investors. The stock has fallen nearly 30% in the past month, dropped 13.4% in the last week, and dipped almost 2% Monday on growing doubts the company can even stay in business.
Top 10 Forestry Stocks To Buy For 2014: National Oxygen Ltd (NOL)
National Oxygen Limited (NOL) is an India-based company, which is a producer and supplier of industrial gases both in liquid and gaseous forms to industries and hospitals. Its products include oxygen, nitrogen and acetylene. The Company operates in two segments: Industrial Gases, which is engaged in the manufacture of industrial gases, and Windmill, which is engaged in the generation of windmill energy. During the fiscal year ended March 31, 2012 (fiscal 2012), the Company produced 51,07,981 cubic meters of oxygen, 52,138 cubic meters of dissolved acetylene, 30,69,610 cubic meters of nitrogen and 26,86,762 kilowatt hours of windmill energy. It has two industrial gas plants in Tamil Nadu and Pondicherry, and one windmill in Maharashtra. During fiscal 2012, NOL had an installed capacity to produce 2,50,00,000 cubic meters of oxygen, 2,00,000 cubic meters of dissolved acetylene and 44,00,000 kilowatt hours of windmill energy.
Advisors' Opinion: Top 10 Forestry Stocks To Buy For 2014: Rovi Corporation(ROVI)
Rovi Corporation provides digital entertainment technology solutions for the discovery and management of entertainment content. It offers interactive program guides; embedded licensing technologies, such as recommendations and search capability; media recognition technologies; licensing of the company?s database of descriptive information about television, movie, music, books, and game content; and analog content protection technologies and services. The company?s interactive program guides technology is an interactive listing of television or video program information that enables viewers to navigate through, sort, select, and schedule video programming for viewing and recording. The company also provides video delivery solutions, such as compression-decompression technology (codec) to enable distribution of content across the Internet and through recordable media in physical or streamed forms; and media manager, a personal computer application enabling consumers to man age personal media files, including music, photos, and video files. In addition, it offers digital copy solution for consumer electronics devices and PC software applications; the Rovi Entertainment Store video delivery solutions; content authoring solutions; and advertising solutions. Rovi Corporation primarily serves companies in the consumer electronics, cable and satellite, entertainment, and online distribution markets. The company was formerly known as Macrovision Solutions Corporation and changed its name to Rovi Corporation in July 2009. Rovi Corporation was founded in 1983 and is headquartered in Santa Clara, California.
Advisors' Opinion: Top 10 Forestry Stocks To Buy For 2014: Bioanalytical Systems Inc.(BASI)
Bioanalytical Systems, Inc. provides drug discovery and development services for pharmaceutical, biotechnology, academic, and government organizations primarily in North America, the Pacific Rim, and Europe. The company operates in two segments, Contract Research Services and Research Products. The Contract Research Services segment offers various services, including product characterization, method development, and validation; bioanalytical testing to measure drug and metabolite concentrations in complex biological matrices; stability testing to establish and confirm product purity, potency, and shelf life; in vivo sampling services for the continuous monitoring of chemical changes in life; and pharmacokinetic and safety testing services, as well as provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing services. The Research Products segment offers analytical products compris ing liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products, such as Culex family of automated in vivo sampling and dosing instruments; and Vetronics? products consisting of instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs. The company was founded in 1974 and is headquartered in West Lafayette, Indiana.
Advisors' Opinion: - [By Laura Brodbeck]
Monday
Earnings Releases Expected: Steelcase (NYSE: SCS), Bioanalytical Systems (NASDAQ: BASI) Economic Releases Expected: Italian trade balance, Greek current account, US existing home sales Tuesday
Top 10 Forestry Stocks To Buy For 2014: Radware Ltd.(RDWR)
Radware Ltd. provides application delivery solutions and network security solutions to banks, insurance companies, manufacturing and retail, government agencies, media companies, and service providers worldwide. The company offers AppDirector Intelligent Application Delivery Controller for data center optimization and to eliminate traffic surges, server bottlenecks, connectivity disconnects, and downtime for business continuity; and Alteon Application Switch application delivery controller that supports local, global, and transparent load-balance, multi-homing network load-balance, and bandwidth management capabilities. It also provides AppXML, which offers XML and Web services communications for mission-critical applications; AppWall, a Web application firewall (WAF) appliance that secures Web applications; LinkProof that manages wide area networks and Internet traffic for networks; Content Inspection Director, a smart redirection and dynamic policy enforcement device to meet contemporary carrier needs; and Session Initiation Protocol Director, an application delivery controller for application vendors, telecom equipment manufacturers, and system integrators. In addition, the company offers DefensePro Intrusion Prevention and Denial of Service products that protect against worms, bots, viruses, malicious intrusions, and DOS attacks; Inflight, a hardware device that provides online and network-based monitoring solutions; and APSolute Vision, an appliance-based management and monitoring system for information technology staff to centrally manage distributed devices and check the performance and security of enterprise wide application delivery infrastructures. It markets and sells its products primarily through distributors and resellers in North America, Europe, and Asia, as well as directly to select customers in the United States. Radware Ltd. was founded in 1996 and is headquartered in Tel Aviv, Israel.
Advisors' Opinion: - [By Seth Jayson]
Radware (Nasdaq: RDWR ) reported earnings on July 25. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Radware met expectations on revenues and missed estimates on earnings per share.
Top 10 Forestry Stocks To Buy For 2014: Emeritus Corporation (ESC)
Emeritus Corporation operates senior living communities in the United States. The company�s communities offer Alzheimer�s and dementia care, independent living, assisted living, specialized memory care, and skilled nursing care services. It also provides management services to independent and related-party owners of assisted living communities. As of November 15, 2012, the company operated approximately 470 senior living communities in 44 states with a resident capacity for approximately 50,000 residents. Emeritus Corporation was founded in 1993 and is headquartered in Seattle, Washington.
Advisors' Opinion: - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Emeritus (NYSE: ESC ) , whose recent revenue and earnings are plotted below.
- [By Sean Williams]
One company with seemingly limitless upside potential today was senior housing operator Emeritus (NYSE: ESC ) , which gained 35.2% after agreeing to be purchased by Brookdale Senior Living (NYSE: BKD ) for $1.4 billion, excluding debt. Under the terms of the deal, Emeritus shareholders will receive 0.95 shares of Brookdale, and would effectively own 23% of the outstanding shares of the company once the merger is complete. Brookdale anticipates the deal being EPS neutral in 2014, and forecasts it adding $0.40 in EPS by the third year. The move certainly makes sense on paper, as cost synergies will help these two senior housing companies fight back against the expectation of declining Medicare reimbursement rates. However, over the long run, the Medicare reimbursement picture is still very cloudy, making Brookdale a riskier buy at the moment following today's announcement.
